Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | +3.40% | -3.18% | +9.60% |
May. 30 | Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results | CI |
May. 15 | Transcript : OncoCyte Corporation, Q1 2024 Earnings Call, May 15, 2024 |
Business Summary
Number of employees: 45
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Tests
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +56.89% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
61.0
%
| 1 | 76.5 % | 1 | 61.0 % | +25.24% |
Non-United States
39.0
%
| 0 | 23.5 % | 1 | 39.0 % | +160.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
James Liu
DFI | Director of Finance/CFO | 29 | 21-06-30 |
Yuh-Min Chiang
CTO | Chief Tech/Sci/R&D Officer | - | 21-08-31 |
Ekkehard Schütz
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Peter Hong
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Last
BRD | Director/Board Member | 64 | 15-12-22 |
Louis Silverman
BRD | Director/Board Member | 65 | 22-11-29 |
Andy Arno
CHM | Chairman | 64 | 15-05-31 |
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,364,637 | 11,653,696 ( 87.20 %) | 0 | 87.20 % |
Stock B | 0 | 5,000 | 0 | 0 |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.60% | 36.62M | |
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.48B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M |
- Stock Market
- Equities
- OCX Stock
- Company OncoCyte Corporation